Quick refresher.
T cell engagers work by grabbing a T cell with one hand and a tumor cell with the other. They’ve been transformative in blood cancers.
Solid tumors?
Not so much.
The targets on solid tumor surfaces are either shared with healthy tissue (hello, toxicity) or the tumor just stops expressing them (hello, escape).
In 2022, Immunocore’s tebentafusp (KIMMTRAK) proved something important: you can build a TCE that targets intracellular cancer antigens by going after peptide-MHC complexes on the cell surface.
It got FDA approval for uveal melanoma.
That opened a door.
But tebentafusp hits one target.
One pMHC.
If the tumor heterogeneity is high or that antigen gets downregulated, you’re back to square one.
Deck Bio thinks the answer is hitting multiple intracellular targets at once.
With one molecule.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
Their lead asset DBXO-1 is a multi-target pMHC-directed T cell engager built with proprietary TCR specificity engineering. One engineered binder that recognizes multiple tumor-specific peptide-MHC complexes simultaneously.
The targets are intracellular cancer antigens that conventional antibodies literally cannot reach.
First indications: NSCLC and gastroesophageal cancer.
A 2023 paper in Cell showed this kind of multi-target pMHC recognition happens naturally in some T cell receptors. But engineering it deliberately into a therapeutic molecule?
That appears to be what Deck Bio is claiming, and it would be a first.
The Cambridge company has been building this since 2023 on about $3.1 million from Mission BioCapital, the American Cancer Society’s venture arm BrightEdge, and Impact Ventures Partners Fund.
The competitive context is actually pretty important here.
- BMS paid Janux up to $850M for masked TCE tech.
- Sanofi licensed Kali’s tri-specific engager.
- CorreGene is filing an IND for a single-target pMHC TCE (CRPA1A2 against MAGE-A1).
Everyone is trying to crack solid tumors with T cell engagers. But most are still working one target at a time.
If Deck Bio’s multi-target approach holds up in the preclinical data they’re presenting at AACR 2026, it could change how the field thinks about antigen escape entirely.
The Biotech Voyager Podcast
Deep dives on the signals shaping early-stage biotech.
